iBio, Inc.
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10,680.0% | – | – | -2,773.7% | – | -1,934.5% | – | -2,307.5% | -5,665.0% | – | – | – | -23,218.0% | |
| 636.0% | – | – | 160.6% | – | 140.5% | – | 142.5% | 289.0% | – | – | – | 549.0% | |
| 1,530.0% | – | – | 205.7% | – | 237.5% | – | 135.0% | 323.0% | – | – | – | 1,373.0% | |
| -1,390.0% | – | – | -1,284.6% | – | -123.5% | – | 4.0% | -529.0% | – | – | – | 2,522.0% | |
| 0.0% | – | – | 120.0% | – | 0.5% | – | 0.5% | 32.0% | – | – | – | 578.0% | |
| 100.0% | – | – | -82.3% | – | -1.0% | – | 22.5% | -21,493.0% | – | – | – | -31,999.0% | |
| – | – | – | 26.3% | – | – | – | 0.0% | – | – | – | – | – | |
| – | – | – | – | – | -85.0% | – | -91.5% | -160.0% | – | – | – | 14,516.0% | |
| 4,944.0% | – | – | 7,424.0% | – | -76.0% | – | 4,090.0% | 46,705.0% | – | – | – | 103,048.0% | |
| -5,636.0% | – | – | 4,568.0% | – | -2,011.5% | – | 1,805.0% | 19,547.0% | – | – | – | 47,831.0% | |
| -10,680.0% | – | – | -2,893.7% | – | -1,935.0% | – | -2,308.0% | -5,697.0% | – | – | – | -23,796.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.